



COST Action CM1103

Structure-based drug design for diagnosis and treatment of neurological diseases:
dissecting and modulating complex function in the monoaminergic systems of the brain


“Mediterranean Neuroscience Society

Santa Margherita di Pula 11-15th Italy




COST Domain - Chemistry and Molecular Sciences and Technologies (CMST)

Inhibition of tau protein hyperphosphorylation as a therapeutic target in Alzheimer's disease




*Mirjana Babić Leko, mag.biol.mol.
Croatian Institute for Brain Research
University of Zagreb Medical School*







The effect of ASS234 on tau phosphorylation *in vitro*




The effect of a) 12 h, b) 18 h and c) 24 h treatment with 30 nM OA on cell viability in combination with 1h pretreatment and cotreatment with 5 μM and 10 μM ASS234.



SH-SY5Y cell viability after 24 h treatment with 5 μ M and 10 μ M ASS234.



SH-SY5Y cell viability after 1 h pretreatment with 5, 10, 20 and 50 μ M ASS234, followed by 24 h in serum-free medium.




- **Compound ASS234 showed no effect on tau protein phosphorylation at epitope S199.**
- **Further studies should be performed to determine the effect of ASS234 on tau phosphorylation induced in SH-SY5Y cells with different compounds (such as nocodazole or formaldehyde).**

The effect of ASS234 no tau protein phosphorylation at epitope S199.



Acknowledgements



Croatian Science Foundation

prof. José Marco-Contelles

**Laboratorio de Química Médica y Computacional
(IQOG, CSIC), Madrid, Spain**

prof. Danka Grčević

University of Zagreb Medical School

prof. Dora Višnjić

University of Zagreb Medical School